Clinical Trials Logo

Aggressive Lymphoma clinical trials

View clinical trials related to Aggressive Lymphoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05412290 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

Start date: December 22, 2022
Phase: Phase 1
Study type: Interventional

This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead.

NCT ID: NCT05020678 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Start date: August 20, 2021
Phase: Phase 1
Study type: Interventional

This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)

NCT ID: NCT03492125 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Study Of The Selective PKC-β Inhibitor MS- 553

Start date: May 25, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/II Dose-Escalation and Expansion Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma